Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether the combination of grass allergen
sublingual immunotherapy (SLIT) and dupilumab for 2 years is more effective than double
placebo in suppressing the nasal allergen challenge (NAC) response to grass pollen at 1 year
after completion of study medication.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
ALK-Abelló A/S Immune Tolerance Network (ITN) PPD Regeneron Pharmaceuticals Rho Federal Systems Division, Inc.